Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ann Hanham Insider Profile

4 Followers

Ann Hanham, Director at SCYNEXIS, holds 11.58K shares in SCYNEXIS (Ticker: SCYX), holds 7.30K shares in HTG Molecular Diagnostics (Ticker: HTGMQ), holds 2.25K shares in Endocyte (Ticker: ECYT).

Ann Hanham's Trading History

SCYXSCYNEXIS		Jun 30, 2026DirectorUninformative Buy―$43.65K
HTGMQHTG Molecular Diagnostics		Aug 16, 2019DirectorUninformative Buy――
ECYTEndocyte		May 05, 2017―Uninformative Buy―$53.98K
BMTIBiomimetic Therapeutics		――――
GYREGyre Therapeutics		―Director―$3.55M
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Ann Hanham insider profile FAQ

What is the percentage of profitable transactions made by Ann Hanham?
The percentage of profitable transactions made by Ann Hanham is 0%.
What is the average return per transaction made by Ann Hanham?
The average return per transaction made by Ann Hanham is -29.10%.
What stocks does Ann Hanham hold?
Ann Hanham holds: SCYX, ECYT, HTGMQ, GYRE, BMTI stocks.
What was Ann Hanham's most profitable transaction?
Ann Hanham’s most profitable transaction was an Informative Buy of SCYX stock on December 23, 2020. The return on the trade was -4.20%.
What is Ann Hanham's role in SCYNEXIS?
Ann Hanham's role in SCYNEXIS is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.